6748 Stock Overview
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ACRO Biomedical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.95 |
| 52 Week High | NT$46.45 |
| 52 Week Low | NT$24.70 |
| Beta | 0 |
| 1 Month Change | -12.95% |
| 3 Month Change | -15.30% |
| 1 Year Change | 21.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6748 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -13.5% | 3.2% | 1.1% |
| 1Y | 21.4% | -24.1% | 28.2% |
Return vs Industry: 6748 exceeded the TW Biotechs industry which returned -24.1% over the past year.
Return vs Market: 6748 underperformed the TW Market which returned 28.2% over the past year.
Price Volatility
| 6748 volatility | |
|---|---|
| 6748 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6748 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6748's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | n/a | www.acrobiomedical.com |
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. Fundamentals Summary
| 6748 fundamental statistics | |
|---|---|
| Market cap | NT$2.02b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6748 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6748 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6748 perform over the long term?
See historical performance and comparison